The state awarded a $50 million contract to produce less costly treatments, but moves by major suppliers might undercut the initiative before any new product emerges.
California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cuts
The New York Times – Business:
This post first appeared in The New York Times – Business. Read the original article.
Written by
in